Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC By Ogkologos - August 27, 2025 440 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PEACE-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy MOST POPULAR Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up August 5, 2025 News digest – skin cancer deaths, Public Health England plans and... August 22, 2020 New on NCI’s Websites for August 2024 August 16, 2024 Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC June 6, 2025 Load more HOT NEWS For Early-Stage Cervical Cancer, Minimally Invasive Surgery Declining Rare Disease Day 2026: Advancing equity for people living with rare... Young Mom-of-Three Learns She Has Stage 4 Breast Cancer, 5 Days... Sublobar Resection Noninferior to Lobectomy in Terms of DFS Among Patients...
